These findings suggest that S:E fusion-positive prostate cancer might be more favorable for bone metastasis, and downregulation of PDGFR and FZD8 by imatinib may protect from bone metastasis, which is a topic for future study. The gene discussed is PDGFRB; the disease is prostate carcinoma.